{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:56:14Z","timestamp":1789692974865,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vaccine.2025.127938","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:10:39Z","timestamp":1762341039000},"page":"127938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development"],"prefix":"10.1016","volume":"68","author":[{"given":"Randall J.","family":"Nett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Agnihothram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.T.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Barzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Monath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Prutzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Erin","family":"Staples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7001a1","article-title":"Surveillance for West Nile virus disease - United States, 2009-2018","volume":"70","author":"McDonald","year":"2021","journal-title":"MMWR Surveill Summ"},{"issue":"18","key":"10.1016\/j.vaccine.2025.127938_bb0010","doi-asserted-by":"crossref","first-page":"628","DOI":"10.15585\/mmwr.mm7118a3","article-title":"West Nile virus and other domestic nationally notifiable arboviral diseases - United States, 2020","volume":"71","author":"Soto","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/v6020606","article-title":"Clinical manifestations and outcomes of West Nile virus infection","volume":"6","author":"Sejvar","year":"2014","journal-title":"Viruses"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127938_bb0020","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1017\/S0950268816001138","article-title":"Hospital-based enhanced surveillance for West Nile virus neuroinvasive disease","volume":"144","author":"Lindsey","year":"2016","journal-title":"Epidemiol Infect"},{"issue":"38","key":"10.1016\/j.vaccine.2025.127938_bb0025","first-page":"845","article-title":"Outbreak of West Nile-like viral encephalitis--New York","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep 1999"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127938_bb0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3201\/eid0505.990505","article-title":"West Nile fever--a reemerging mosquito-borne viral disease in Europe","volume":"5","author":"Hubalek","year":"1999","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127938_bb0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10096-003-1085-1","article-title":"West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas","volume":"23","author":"Zeller","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127938_bb0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jiph.2024.03.012","article-title":"Do we protect ourselves against West Nile virus? A systematic review on knowledge, attitudes, and practices and their determinants","volume":"17","author":"Fonzo","year":"2024","journal-title":"J Infect Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127938_bb0045","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3201\/eid1405.071347","article-title":"Efficacy of aerial spraying of mosquito adulticide in reducing incidence of West Nile virus, California, 2005","volume":"14","author":"Carney","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1051\/vetres:2006045","article-title":"Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California","volume":"38","author":"Gardner","year":"2007","journal-title":"Vet Res"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127938_bb0080","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.vaccine.2006.11.056","article-title":"Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection","volume":"25","author":"Chang","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127938_bb0085","article-title":"Current progress of avian vaccines against West Nile virus","volume":"7","author":"Jimenez de Oya","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"18","key":"10.1016\/j.vaccine.2025.127938_bb0090","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJMp2301816","article-title":"Combating West Nile virus disease \u2014 time to revisit vaccination","volume":"388","author":"Gould","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127938_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/v11090823","article-title":"Twenty years of progress toward West Nile virus vaccine development","volume":"11","author":"Kaiser","year":"2019","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127938_bb0100","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jama.2025.8737","article-title":"West Nile virus: a review","volume":"334","author":"Gould","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0105","first-page":"1","article-title":"Surveillance for human West Nile virus disease \u2014 United States, 1999-2008","volume":"59","author":"Lindsey","year":"2010","journal-title":"MMWR Surveill Summ"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127938_bb0110","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/cid\/ciac766","article-title":"Severe arboviral neuroinvasive disease in patients on rituximab therapy: a review","volume":"76","author":"Kapadia","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.2012.12-0113","article-title":"Medical risk factors for severe West Nile virus disease, United States, 2008-2010","volume":"87","author":"Lindsey","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3201\/eid2802.211697","article-title":"West Nile virus transmission by solid organ transplantation and considerations for organ donor screening practices","volume":"28","author":"Soto","year":"2022","journal-title":"United States Emerg Infect Dis"},{"issue":"34","key":"10.1016\/j.vaccine.2025.127938_bb0125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.15585\/mmwr.mm7234a1","article-title":"West Nile virus and other nationally notifiable arboviral diseases \u2014 United States, 2021","volume":"72","author":"Fagre","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127938_bb0135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.15585\/mmwr.mm7217a1","article-title":"Unprecedented outbreak of West Nile virus \u2014 Maricopa County, Arizona, 2021","volume":"72","author":"Kretschmer","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13071-022-05630-y","article-title":"Evaluation of an open forecasting challenge to assess skill of West Nile virus neuroinvasive disease prediction","volume":"16","author":"Holcomb","year":"2023","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2025.127938_bb0145","article-title":"Multi-model prediction of West Nile virus neuroinvasive disease with machine learning for identification of important regional climatic drivers","volume":"7(11):e2023GH000906","author":"Holcomb","year":"2023","journal-title":"Geohealth"},{"key":"10.1016\/j.vaccine.2025.127938_bb0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcv.2018.08.007","article-title":"Ongoing and emerging arbovirus threats in Europe","volume":"107","author":"Barzon","year":"2018","journal-title":"J Clin Virol"},{"issue":"48","key":"10.1016\/j.vaccine.2025.127938_bb0160","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.48.2300258","article-title":"Ecological and clinical evidence of the establishment of West Nile virus in a large urban area in Europe, Berlin, Germany, 2021 to 2022","volume":"28","author":"Ruscher","year":"2023","journal-title":"Euro Surveill"},{"issue":"19","key":"10.1016\/j.vaccine.2025.127938_bb0165","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.19.2001095","article-title":"Epidemiology of human West Nile virus infections in the European Union and European Union enlargement countries, 2010 to 2018","volume":"26","author":"Young","year":"2021","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011880","article-title":"West Nile virus spread in Europe: phylogeographic pattern analysis and key drivers","volume":"20","author":"Lu","year":"2024","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127938_bb0175","doi-asserted-by":"crossref","first-page":"taac125","DOI":"10.1093\/jtm\/taac125","article-title":"Rapid spread of a new West Nile virus lineage 1 associated with increased risk of neuroinvasive disease during a large outbreak in northern Italy, 2022: one health analysis","volume":"31","author":"Barzon","year":"2022","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0180","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1038\/s41467-023-42185-7","article-title":"Spatial and temporal dynamics of West Nile virus between Africa and Europe","volume":"14","author":"Mencattelli","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0185","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41467-024-45290-3","article-title":"Contribution of climate change to the spatial expansion of West Nile virus in Europe","volume":"15","author":"Erazo","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127938_bb0190","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.1951.s1-31.724","article-title":"West Nile, Ilheus, and Bunyamwera virus infections in man","volume":"31","author":"Southam","year":"1951","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4269\/ajtmh.1954.3.19","article-title":"Induced virus infections in man by the Egypt isolates of West Nile virus","volume":"3","author":"Southam","year":"1954","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/viro.2002.1372","article-title":"Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype","volume":"296","author":"Beasley","year":"2002","journal-title":"Virology"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2025.127938_bb0205","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1099\/vir.0.063537-0","article-title":"Evaluation of a mouse model for the West Nile virus group for the purpose of determining viral pathotypes","volume":"95","author":"Bingham","year":"2014","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127938_bb0210","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1099\/jgv.0.000743","article-title":"Pathogenicity evaluation of twelve West Nile virus strains belonging to four lineages from five continents in a mouse model: discrimination between three pathogenicity categories","volume":"98","author":"Perez-Ramirez","year":"2017","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127938_bb0215","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1128\/JVI.01112-10","article-title":"Mosquito saliva causes enhancement of West Nile virus infection in mice","volume":"85","author":"Styer","year":"2011","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127938_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00493-15","article-title":"Genetic diversity in the collaborative cross model recapitulates human West Nile virus disease outcomes","volume":"6","author":"Graham","year":"2015","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virol.2011.05.018","article-title":"Transgenic expression of full-length 2\u2032,5\u2032-oligoadenylate synthetase 1b confers to BALB\/c mice resistance against West Nile virus-induced encephalitis","volume":"417","author":"Simon-Chazottes","year":"2011","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127938_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024745","article-title":"Host genetic risk factors for West Nile virus infection and disease progression","volume":"6","author":"Bigham","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000321","article-title":"Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man","volume":"5","author":"Lim","year":"2009","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127938_bb0240","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1086\/497340","article-title":"Single nucleotide polymorphisms in genes for 2\u2032-5\u2032-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection","volume":"192","author":"Yakub","year":"2005","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127938_bb0245","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/infdis\/jiy623","article-title":"Immune correlates of protection from West Nile virus Neuroinvasion and disease","volume":"219","author":"Graham","year":"2019","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127938_bb0250","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1534\/g3.117.041624","article-title":"Oas1b-dependent immune transcriptional profiles of West Nile virus infection in the collaborative cross","volume":"7","author":"Green","year":"2017","journal-title":"G3 (Bethesda)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0255","first-page":"152","article-title":"Characterization of West Nile virus persistent infections in genetically resistant and susceptible mouse cells","volume":"140","author":"Brinton","year":"1985","journal-title":"II Generation of temperature-sensitive mutants Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127938_bb0260","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3201\/eid0911.030226","article-title":"West Nile virus infection in nonhuman primate breeding colony, concurrent with human epidemic, southern Louisiana","volume":"9","author":"Ratterree","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127938_bb0265","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1086\/381461","article-title":"Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection","volume":"189","author":"Ratterree","year":"2004","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127938_bb0270","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1128\/JVI.00172-08","article-title":"Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates","volume":"82","author":"Maximova","year":"2008","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127938_bb0275","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/088282403322396082","article-title":"Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus","volume":"16","author":"Diamond","year":"2003","journal-title":"Viral Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrmicro2950","article-title":"West Nile virus infection and immunity","volume":"11","author":"Suthar","year":"2013","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000757","article-title":"IPS-1 is essential for the control of West Nile virus infection and immunity","volume":"6","author":"Suthar","year":"2010","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127938_bb0290","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127938_bb0295","series-title":"Guidance for industry expedited programs for serious conditions \u2014 Drugs and biologics silver spring","author":"Food and Drug Administration","year":"2014"},{"issue":"50","key":"10.1016\/j.vaccine.2025.127938_bb0300","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2018.10.033","article-title":"Defining a correlate of protection for chikungunya virus vaccines","volume":"37","author":"Milligan","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127938_bb0305","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4049\/jimmunol.135.4.2805","article-title":"Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48","volume":"135","author":"Schlesinger","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127938_bb0310","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-9-18","article-title":"Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection","volume":"9","author":"Ben-Nathan","year":"2009","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127938_bb0315","author":"Association of Public Health Laboratories"},{"key":"10.1016\/j.vaccine.2025.127938_bb0320","series-title":"Laboratory diagnosis of arboviruses. Arboviruses: Molecular biology, evolution and control","first-page":"271","author":"Lambert","year":"2016"},{"key":"10.1016\/j.vaccine.2025.127938_bb0325","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.3389\/fmicb.2018.02421","article-title":"Surveillance and diagnosis of West Nile virus in the face of flavivirus cross-reactivity","volume":"9","author":"Lustig","year":"2018","journal-title":"Front Microbiol"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2025.127938_bb0330","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.vaccine.2004.03.027","article-title":"Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine","volume":"22","author":"Beasley","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0335","doi-asserted-by":"crossref","first-page":"2343910","DOI":"10.1080\/22221751.2024.2343910","article-title":"Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus","volume":"13","author":"Kim","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"45","key":"10.1016\/j.vaccine.2025.127938_bb0340","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127938_bb0345","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2032-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/vbz.2005.5.1","article-title":"Infectivity of West Nile\/dengue chimeric viruses for West Nile and dengue mosquito vectors","volume":"5","author":"Hanley","year":"2005","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2025.127938_bb0355","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/j.vaccine.2014.04.002","article-title":"Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN\/DEN4Delta30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine","volume":"32","author":"Maximova","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127938_bb0360","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1073\/pnas.022652799","article-title":"West Nile virus\/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy","volume":"99","author":"Pletnev","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"48","key":"10.1016\/j.vaccine.2025.127938_bb0365","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127938_bb0370","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/infdis\/jiw501","article-title":"A live attenuated chimeric West Nile virus vaccine, rWN\/DEN4Delta30, is well tolerated and immunogenic in flavivirus-naive older adult volunteers","volume":"215","author":"Pierce","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127938_bb0375","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1471-4914(01)02048-2","article-title":"Yellow fever vector live-virus vaccines: West Nile virus vaccine development","volume":"7","author":"Arroyo","year":"2001","journal-title":"Trends Mol Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127938_bb0380","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-055522","article-title":"Dengue: a growing problem with new interventions","volume":"149","author":"Wong","year":"2022","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127938_bb0385","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.vaccine.2015.07.057","article-title":"Japanese encephalitis vaccines: WHO position paper, February 2015 \u2014 recommendations","volume":"34","author":"World Health Organization","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127938_bb0390","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/v5123048","article-title":"Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus","volume":"5","author":"Dayan","year":"2013","journal-title":"Viruses"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127938_bb0395","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127938_bb0400","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JVI.75.9.4040-4047.2001","article-title":"West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays","volume":"75","author":"Davis","year":"2001","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127938_bb0405","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127938_bb0410","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127938_bb0415","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127938_bb0420","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4269\/ajtmh.2008.79.955","article-title":"Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters","volume":"79","author":"Siirin","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127938_bb0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-018-0077-1","article-title":"A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile virus antigen","volume":"3","author":"Van Hoeven","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127938_bb0435","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127938_bb0440","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2016.11.080","article-title":"Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine","volume":"35","author":"Poore","year":"2017","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2025.127938_bb0445","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1016\/j.vaccine.2018.12.026","article-title":"An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus vaccine, HydroVax-001, in healthy adults","volume":"37","author":"Woods","year":"2019","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2025.127938_bb0450","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.vaccine.2018.12.020","article-title":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine","volume":"37","author":"Quintel","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127938_bb0455","author":"Baxter"},{"key":"10.1016\/j.vaccine.2025.127938_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104375","article-title":"Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: a randomized, double-blind, placebo-controlled phase 1 trial","volume":"86","author":"Friedman-Klabanoff","year":"2022","journal-title":"EBioMedicine"},{"issue":"37","key":"10.1016\/j.vaccine.2025.127938_bb0465","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1016\/j.vaccine.2017.07.065","article-title":"Regulatory considerations in development of vaccines to prevent disease caused by chikungunya virus","volume":"35","author":"Yang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127938_bb0470","author":"Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2025.127938_bb0475","author":"Food and Drug Administration"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127938_bb0495","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/cid\/ciab540","article-title":"Cost-effectiveness and impact of a targeted age- and incidence-based West Nile virus vaccine strategy","volume":"73","author":"Curren","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2025.127938_bb0500","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2016.11.078","article-title":"Cost effectiveness of a targeted age-based West Nile virus vaccination program","volume":"35","author":"Shankar","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127938_bb0505","series-title":"Centers for Disease Control and Prevention. The National Public Health Strategy to prevent and control vector-borne diseases in people. U.S","author":"The U.S. Department of Health and Human Services and the U.S","year":"2024"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:28:08Z","timestamp":1781663288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25012356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":90,"alternative-id":["S0264410X25012356"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127938","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127938"}}